Pasithea Therapeutics Corp. (NASDAQ:KTTA) Sees Significant Increase in Short Interest

Pasithea Therapeutics Corp. (NASDAQ:KTTA) saw a significant growth in short interest in the month of January. As of January 15th, there was short interest totalling 25,800 shares, a growth of 37.2% from the December 31st total of 18,800 shares. Based on an average daily volume of 40,700 shares, the short-interest ratio is presently 0.6 days. Currently, 2.5% of the company’s shares are sold short.

Pasithea Therapeutics Trading Down 0.4 %

NASDAQ:KTTA opened at $2.24 on Friday. The company’s 50-day moving average is $2.72 and its two-hundred day moving average is $3.88. Pasithea Therapeutics has a 1-year low of $2.19 and a 1-year high of $9.25.

Pasithea Therapeutics Company Profile

Pasithea Therapeutics Corp., a biotechnology company, engages in discovery, research, and development of treatments for central nervous system disorders, RASopathies, and other diseases. Its lead product candidate PAS-004, a next-generation macrocyclic mitogen-activated protein kinase, or MEK inhibitor for use in the treatment of a range of RASopathies, including neurofibromatosis type 1 oncology indications.